Background: Neutrophils play substantial roles in cancer progression. Previous reports demonstrated the prognostic impact of the pretreatment neutrophil-tolymphocyte ratio (NLR) in various types of solid cancers. The purpose of this study was to quantify the prognostic impact of NLR on head and neck squamous cell carcinoma (HNSCC).
| I NT ROD UCTI ON
The immune system protects the host from environmental agents and is also involved in tissue repair. Leukocytes play a pivotal role in the immune response. The immune system has suppressive roles in carcinogenesis and tumor progression. 1 First, the immune system prevents infection by microorganisms, several of which are associated with carcinogenesis. Second, immune cells can recognize and kill tumor cells. Tumor cells regulate the immune system around them and create an inflammatory microenvironment to facilitate tumor progression. 2 Thus, the immune system plays a dual role in cancer progression. The classical type of head and neck squamous cell carcinoma (HNSCC) is caused mainly by habitual smoking and drinking alcohol. These carcinogens cause chronic inflammation of the upper aerodigestive tract, resulting in the oncogenesis of epithelial cells. A new type of HNSCC, which has increased in recent decades, is caused by human papillomavirus (HPV). 3 Both types of HNSCC are closely associated with the immune system and the inflammatory process. Accumulating evidence indicates that several inflammatory markers can predict the prognosis of various types of cancer. [4] [5] [6] [7] The neutrophil-to-lymphocyte ratio (NLR) in peripheral blood is one of the most extensively investigated markers because it is easily calculated from routine blood examination results. A meta-analysis by Templeton et al 6 demonstrated that a high NLR is associated with poor prognosis in many solid tumors. However, their analysis included only a few studies on HNSCC. Increasing numbers of studies on the association between NLR and HNSCC prognosis have been published, but these studies have had inconsistent results.
In the present work, our purpose was to resolve the discrepancy and to quantify the prognostic value of NLR in patients with HNSCC by using meta-analytic techniques.
| M ATE RI ALS AN D ME THO DS

| Search strategy
This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. 8 We performed a literature search regarding the association of HNSCC and NLR using electronic databases for articles published between January 1, 2000, and December 31, 2016. The databases used were PubMed (www.ncbi. nlm.nih.gov/pubmed) and Scopus (www.elsevier.com/onlinetools/scopus). The search terms were "head and neck," "larynx," "laryngeal," "oropharynx," "oropharyngeal," "hypopharynx," "hypopharyngeal," "oral," "tongue," "parotid," "salivary gland," "nasal," "paranasal," "tumor," "malignancy," "cancer," "neutrophil," and "lymphocyte." The references in the retrieved articles were manually searched for associated studies.
| Study selection
The inclusion criteria were as follows: (1) studies reporting the prognostic impact of pretreatment NLR in peripheral blood on head and neck cancer; (2) a hazard ratio (HR) and 95% confidence interval (CI) or a P value for overall survival (OS) or disease-specific survival (DSS) were available; and (3) the histological types of the tumors were considered to be predominantly squamous cell carcinoma (SCC). The exclusion criteria were as follows: (1) nonhuman studies and those in languages other than English; (2) studies focusing on thyroid cancer or nasopharyngeal cancer; and (3) studies focusing on salivary gland cancer or nasal and paranasal cancer in which SCC and non-SCC were analyzed together. Two of the authors (Y.T. and O.R.) evaluated the electronically searched titles independently. All potentially relevant publications were retrieved in full. Inter-reviewer agreement was assessed by Cohen's kappa. Disagreement was resolved by consensus.
| Data extraction
The following data were extracted: name of first author; year of publication; number of patients; primary tumor site; disease stage; treatment modality; cutoff methods and cutoff values for NLR; and HRs, 95% CIs, and P values for OS and DSS. The HRs, 95% CIs, and P values were extracted preferentially from multivariate analyses. Otherwise, the HRs were extracted from univariate analyses.
| Statistical analysis
Meta-analyses were performed with a random effect model using Comprehensive Meta-Analysis (Biostat, Englewood, NJ). The meta-analysis was conducted initially in all included studies for OS and DSS. Two studies divided patients into 3 or 4 groups and showed HRs compared with the lowest NLR group. 9, 10 For these studies, the weighted means of HRs were used as the representatives of these studies. 11 One study showed the results for 2 different NLR cutoff values, 1 cut-off value determined by receiver operating characteristic and the other determined by literature review.
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The former result was used for the data synthesis of our study. Subgroup analyses were conducted for disease site, disease stage, treatment modality, NLR cutoff value, and whether the HR data were derived from univariate or multivariate analysis. Not all studies were subjected to subgroup analyses because the present study was not an individual patient data meta-analysis and several individual studies report the HR of patients with different characteristics together. Publication bias was assessed by the funnel plot and tested by an Egger's regression intercept test. Heterogeneity was assessed by Cochran Q and I 2 statistics. All statistical tests were 2-sided, and statistical significance was defined by a P value of < .05.
| RES U LTS
| Literature search results
Electronic database searches retrieved 704 records (see Figure 1) . We examined the titles and abstracts, and excluded duplicated entries, review articles, and articles written in languages other than English. The full texts of 36 studies were then inspected. After excluding studies according to the Abbreviations: (C)RT, (chemo)radiotherapy; DSS, disease-specific survival; HR, hazard ratio; OS, overall survival; ROC, receiver operating characteristic.
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exclusion criteria, 19 studies enrolling 3770 patients were included in the present study (see Table 1 ). 9,10,12-28 Cohen's kappa for inter-reviewer agreement was 0.88. Table 1 shows the characteristics of the included studies. Only 6 studies were published before 2016, and 13 studies were published in 2016. DSS was investigated in 5 studies, and OS was investigated in 16 studies. The included stages were early stage in 1 study, advanced stage in 4 studies, and mixed early and advanced stages in 14 studies. The treatment modalities in these studies were radiotherapy (with or without chemotherapy) in 6 studies, surgery (with or without postoperative radiotherapy) in 7 studies, and mixed in 6 studies. The median cutoff value for NLR was 2.52. The HR was calculated by multivariate analysis in 14 studies and by univariate analysis in 5 studies. In all included studies, the NLR was measured from pretreatment blood samples. However, the specific time period was described in only 9 studies.
| Characteristics of the selected studies
| Overall survival
The cutoff values of NLR for dichotomization ranged from 1.92 to 5 (median 2.69). Among 16 studies reporting HRs for OS, 4 studies reported statistically nonsignificant HRs. The pooled analysis for the 16 studies enrolling 3371 patients is shown in Figure 2 . Overall, higher NLR was associated with worse OS (HR 1.69; 95% CI 1.47-1.93; P < .001). F IGUR E 2 Forest plot showing hazard ratios (HRs) for overall survival for neutrophil-to-lymphocyte ratio. The squares represent HRs for each study.
| Subgroup analysis for overall survival
The sizes of the squares and the horizontal lines crossing the squares represent the weight of the study in the meta-analysis and the 95% confidence intervals (CIs), respectively
| Disease-specific survival
Five studies enrolling 972 patients, reported HRs for DSS. 14, 15, 20, 24, 25 Two of the 5 studies reported statistically nonsignificant HRs. The cutoff value for NLR ranged from 1.9 to 5 (median 2.80). Figure 3 shows the forest plot for DSS. The combined HR for DSS was 1.88 (95% CI 1.20-2.95; P 5 .006). Figure 4 shows the funnel plots of HRs for OS and DSS. Both plots showed apparent asymmetry, indicating that there was evidence of publication bias, with fewer small studies reporting negative results than would be expected. Egger's test of the intercept suggested the presence of publication bias in OS analysis (P < .001), but not in DSS analysis (P 5
| Publication bias
.059), probably because of the small number of studies reporting DSS and the resultant low statistical power.
| DI S CU S S IO N
Circulating blood contains several types of immune cells, and all of them participate in the immune response. Inflammation is one of the hallmarks of cancer, and immune cells, together with stromal cells, vasculature, lymphatics, and extracellular matrix, constitute the tumor microenvironment. 2 Among the immune cells in the tumor microenvironment, the roles of lymphocytes have been extensively investigated. Lymphocytes infiltrating tumor tissue have tumorsuppressive functions, and increase in tumor-infiltrating lymphocytes (TILs) is associated with better prognosis in many types of cancer. 29 The tumor-suppressive functions of TILs Abbreviations: CI, confidence interval; (C)RT, (chemo)radiotherapy; HR, hazard ratio.
F IGUR E 3 Forest plot showing hazard ratios (HRs) for disease-specific survival for neutrophil-to-lymphocyte ratio. The squares represent the HRs for each study. The sizes of the squares and the horizontal lines crossing the squares represent the weight of the study in the meta-analysis and the 95% confidence intervals (CIs), respectively
are inhibited by the immune evasion systems of the cancer. However, drugs for immunological checkpoint blockade restore the function of TILs and improve the prognosis of several solid cancers, including HNSCC. 30 Neutrophils are also components of the tumor microenvironment, and experimental results have elucidated their role in tumor progression. Tumor-associated neutrophils (TANs) promote tumor growth through angiogenesis, 31 mitogenic molecules, such as neutrophil elastase, 32 and suppression of antitumor immunity. 33 Moreover, TANs promote metastasis through migration of cancer cells, 32 angiotropism, 34 and the premetastatic niche. 35 A portion of these protumor effects is mediated by neutrophil extracellular traps, which are formed by extracellular chromatin and secreted proteases. 36, 37 Thus, TANs promote tumor progression and metastasis, and TANs have been shown to be prognostic markers for a wide range of cancers. 38 Tumor, stromal, and immune cells in the tumor microenvironment secrete cytokines to facilitate the development and release of bone-marrow neutrophils, 39 and the resultant neutrophilia can be used as a diagnostic and prognostic biomarker for HNSCC. Neutrophil counts in the peripheral blood are elevated in patients with laryngeal and oral cancer and can differentiate cancers from benign lesions in the larynx and oral cavity. [40] [41] [42] Increased neutrophil counts were demonstrated to be a prognostic marker in patients with head and neck cancer. 43 The prognostic capability of an increase in neutrophils in blood is further enhanced when the neutrophil count is shown as pretreatment NLR. As shown in Table  1 , the number of studies of NLR in patients with HNSCC is rapidly increasing. However, the study populations, cutoff values, and, as a consequence, the magnitude of NLR are considerably different among studies.
In the present study, we aimed to assess the prognostic impact of NLR on HNSCC by conducting a meta-analysis of 19 studies enrolling 3770 patients. Two-thirds of the studies demonstrated that higher NLR was significantly associated with poor prognosis, whereas others had nonsignificant results. However, both the combined HRs for OS of 16 studies and the combined HRs for DSS of 5 studies showed significantly poorer survival associated with elevated NLRs. The negative impact on survival was consistent among several subgroup analyses. However, the subgroup analysis for tumor sites implied that the magnitude of the impact might be different, depending on the tumor sites.
Templeton et al 6 conducted a meta-analysis to assess the prognostic effect of NLR in patients with solid cancers. They found an association of NLR with poor prognosis, which was consistent among a wide range of cancers. However, the magnitude of the effect on OS was different among cancer sites. Several cancers arise on an inflamed background, and the biological characteristics of tumor cells are quite different among different types of cancer. Therefore, meta-analyses should be conducted separately for each type of cancer. Recent meta-analyses of cancer of the cervix, breast, lung, colorectum, prostate, kidney, esophagus, and liver have been published. [44] [45] [46] [47] [48] [49] [50] [51] [52] The pooled HRs for OS in these studies range from 1.23 to 2.102. The results of our analyses are comparable to those of previously reported meta-analyses of other types of cancer. However, the HRs for OS in the oropharyngeal cancer subgroup was much higher than that in other head and neck subgroups in this study and in subgroups of other cancers in previous studies. 6, [44] [45] [46] [47] [48] [49] [50] [51] [52] One of the reasons for this discrepancy is that the HRs for the oropharyngeal cancer subgroup came from only 1 study enrolling 76 patients. Another reason for the discrepancy is that oropharyngeal cancer consists of 2 distinct types of cancer: HPV-negative oropharyngeal cancer, which is caused by excessive smoking and drinking, and HPV-positive oropharyngeal cancer. 3 Compared with HPV-negative oropharyngeal cancer, HPV-positive oropharyngeal cancer has different clinical characteristics, genetic alterations, and better prognosis and, therefore, could be treated less aggressively. 53, 54 Recent studies revealed that the host immune responses and immune cells in the tumor microenvironment are also different in HPV-negative and HPV-positive oropharyngeal cancer. 54 Rachidi et al 9 showed that NLR was lower in patients with HPV-positive disease than in HPV-negative patients and that the increase in the risk of death with oropharyngeal cancer by HPV status and investigated the prognostic value of circulating neutrophils, monocytes, and lymphocytes in oropharyngeal cancer. They found that the HPV-positive cohort had lower neutrophil counts and monocyte counts and that both elevated circulating neutrophil and monocyte counts were associated with decreased OS in HPV-positive oropharyngeal cancer, but not in HPVnegative oropharyngeal cancer. 43 Collectively, whether it is shown as an absolute count or as a ratio to lymphocytes, the effect of elevated neutrophils on prognosis was larger in HPV-positive oropharyngeal cancer than in HPV-negative oropharyngeal cancer. Therefore, stratification according to HPV status is required for future individual studies.
There are several limitations in this study. First, as shown in Figure 4 , there was a significant publication bias in the present analyses. Further, all included studies were retrospective studies, which may introduce more biased data. Second, we only included studies reporting HRs. Therefore, we excluded studies that reported the prognostic value of NLR only in the Kaplan-Meier estimates. Third, there was heterogeneity among the included studies. As shown in Table 2 , subsites, stage, treatment modalities, cutoff methods, cutoff values, and analysis of HRs were quite different among individual studies. Besides, variables included in the Cox proportional hazard models in individual studies were different. The selection of variables in the multivariate models is very important because different combinations of variables change the HR for NLR. Specifically, inclusion of other inflammation of markers, such as C-reactive protein, plateletlymphocyte ratio, and lymphocyte-macrophage ratio, will diminish the prognostic values of NLR. 22 Fourth, the information on HPV status was absent in almost all studies. The HPV status is one of the most powerful prognostic indicators of HNSCC and was incorporated into the classification of oropharyngeal cancer in the latest edition of TNM staging. 55 However, only 2 studies showed HPV status data. 9, 19 Besides, HPV status was neither included in the multivariate model nor used for stratification in 1 study. 19 In another study, stratification according to HPV status was conducted; however, NLR was included as a continuous variable in the Cox proportional hazard model. 9 Finally, the present analysis is an aggregate data meta-analysis. Because of the nature of the aggregate data, we could not conduct adequate subgroup analysis.
In conclusion, the NLR was significantly associated with a poor prognosis of HNSCC, and its prognostic capability was consistent across different subgroups. Thus, the NLR was demonstrated to be a reliable prognostic marker for HNSCC. In addition to its role as a prognostic marker, the NLR can be used for several clinical applications. First, owing to its prognostic capability, the NLR can be used to select patients for early clinical trials. 56 Second, the NLR can be used as a predictive marker for immunotherapy. Ipilimumab is a monoclonal antibody that blocks the immune checkpoint cytotoxic T lymphocyte antigen 4 and improves survival in patients with metastatic melanoma. 57 Studies of metastatic melanoma suggest that specific types of immune cells in the peripheral blood are associated with the clinical outcome of ipilimumab immunotherapy 58 and, more importantly, that NLR can predict the response to ipilimumab. 59 Ipilimumab is one of the drugs under clinical trial for HNSCC. 60 Therefore, NLR might be used as a predictive marker for HNSCC immunotherapy in the near future. Further research on the association of NLR and HNSCC is required to elucidate the clinical applications of NLR.
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